Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

Pediatrics

Volumn 134, Issue 2, 2014, Pages

  Brady, Michael T ^f   Byington, Carrie L ^f   Davies, H Dele ^f   Edwards, Kathryn M ^f   Jackson, Mary Anne ^f   Maldonado, Yvonne A ^f   Murray, Dennis L ^f   Orenstein, Walter A ^f   Rathore, Mobeen H ^f   Sawyer, Mark H ^f   Schutze, Gordon E ^f   Willoughby, Rodney E ^f   Zaoutis, Theoklis E ^f   Bernstein, Henry H ^f   Kimberlin, David W ^f   Long, Sarah S ^f   Meissner, H Cody ^f   Fischer, Marc A ^a   Gellin, Bruce G ^b   Gorman, Richard L ^c   Lee, Lucia H ^d   Pratt, R Douglas ^d   Read, Jennifer S ^d   Robinson, Joan L ^e   Safadi, Marco Aurelio Palazzi ^f   Seward, Jane F ^a   Starke, Jeffrey R ^g   Simon, Geoffrey R ^h   Tan, Tina Q ⁱ   Bocchini, Joseph A ^f   Morrow, W Robert ^j   Pickering, Larry K ^f   Rosenthal, Geoffrey L ^j   Stewart, Dan L ^f   Winterstein, Almut ^f   Frantz, Jennifer M ^f   Ralston, Shawn L ^f   Lieberthal, Allan S ^f   Alverson, Brian K ^f   Baley, Jill E ^f   Gadomski, Anne M ^f   Johnson, David W ^f   Light, Michael J ^f   Maraqa, Nizar F ^f   Mendonca, Eneida A ^f   Phelan, Kieran J ^f   Zorc, Joseph J ^f   Stanko Lopp, Danette ^f   Hernández Cancio, Sinsi ^f   Brown, Mark A ^f   Nathanson, Ian ^f   Rosenblum, Elizabeth ^f   Sayles III, Stephen ^f   Davidson, Caryn ^f   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b National Vaccine Program Office   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e Canadian Pediatric Society   (Canada)

^f Sociedad Latinoamericana de Infectologia Pediatrica ^*

^g American Thoracic Society   (United States)

^h Committee on Practice Ambulatory Medicine ^*  (United States)

ⁱ Pediatric Infectious Diseases Society   (United States)

^j Section on Cardiology   (United States)

more..

Author keywords

Bronchiolitis; Chronic lung disease; Congenital heart disease; Infants and young children; Palivizumab; Respiratory syncytial virus; RSV

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ALASKA NATIVE; ANTIVIRAL RESISTANCE; ARTICLE; BRONCHIOLITIS; CHILD; CHILDHOOD MORTALITY; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DISEASE SEVERITY; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EPIDEMIC; GESTATIONAL AGE; HEALTH CARE COST; HEART DISEASE; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; INCIDENCE; INFANT; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LUNG HEMODYNAMICS; NEUROMUSCULAR DISEASE; PATHOLOGICAL ANATOMY; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEASONAL VARIATION; SINGLE DRUG DOSE; TREATMENT PLANNING; UNITED STATES; VIRUS ISOLATION; VIRUS RESISTANCE; WHEEZING;

BRONCHIOLITIS; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; INFANTS AND YOUNG CHILDREN; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS; RSV;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84905278885     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-1666     Document Type: Article

References (158)

1. Synagis Package Insert. Gaithersburg, MD: MedImmune; April 2013. Available at: www.medimmune.com/docs/default-source/pdfs/prescribing- information-for-synagis.pdf. Accessed April 24, 2014
2. Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010;84(16):8132-8140
3. IMpact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537
4. Feltes TF, Cabalka AK, Meissner HC, et al Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540 (Pubitemid 37352516)
5. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012:609-618
6. American Academy of Pediatrics. Policy statement: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014; (in press)
7. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211-1216
8. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 pt 1):1442-1446
9. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006:560-566
10. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701
11. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927-4936
12. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity - United States, July 2011-January 2013. MMWR Morb Mortal Wkly Rep. 2013;62(8):141-144
13. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus - United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep. 2011;60(35):1203-1206
14. Hasegawa K, Tsugawa Y, Brown DFM, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics. 2013;132(1):28-36
15. Byington CL, Wilkes J, Sheng X, Korgenski K. Respiratory syncytial virus associated mortality in hospitalized United States infants and children less than 2 years of age. Presented at the Pediatric Academic Societies Annual Meeting; May 4-7, 2013; Washington, DC. Abstract 2915.181
16. Blanken MO, Rovers MM, Molenaar JM, et al Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791-1799
17. Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA; C-CREW Investigators. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132(5):811-818
18. Bloemers BL, van Furth AM, Weijerman ME, et al. High incidence of recurrent wheeze in children with Down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J. 2010;29(1):39-42
19. Megged O, Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J. 2010;29(7):672-673
20. Robinson KA, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2012;2(2):CD007743
21. Zhu Q, McAuliffe JM, Patel NK, et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis. 2011;203(5):674-682
22. Zhu Q, Patel NK, McAuliffe JM, et al. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Infect Dis. 2012;205(4):635-638
23. Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol. 2008;42(1):52-57
24. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4(4):CD006602
25. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):498-505
26. Carroll KN, Griffin MR, Edwards KM, et al. Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties. Pediatr Infect Dis J. 2012;31(11):e229-e231
27. Hampp C, Saidi AS, Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953-959, e1
28. Public Health England. Respiratory syncytial virus. In: Green Book. London, England: Public Health England; 2013:1-13. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/ 148494/Green-Book-Chapter-27a-dh-130131.pdf. Accessed April 24, 2014
29. Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev. 2009;10(3):143-147
30. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510-517
31. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(suppl 5):S127-S132 (Pubitemid 37456910)
32. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446 (Pubitemid 29493797)
33. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31(1):5-9
34. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2). Available at: www.pediatrics.org/cgi/content/full/132/ 2/e341
35. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598
36. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427-1436
37. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2012. Natl Vital Stat Rep. 2013;62(3):1-20
38. Boyce TG, Mellen BG, Mitchel EF, Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137(6):865-870
39. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154(1):55-61 (Pubitemid 30027656)
40. Winterstein AG, Knox CA, Kubilis P, Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr. 2013;167(12):1118-1124
41. Chang RKR, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol. 2010;31(1):90-95
42. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics. 2004;114(6):1606-1611 (Pubitemid 41754926)
43. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects - hospitalizations and costs. Acta Paediatr. 2006;95(4):404-406 (Pubitemid 43739064)
44. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89(10):961-965
45. Geskey JM, Thomas NJ, Brummel GL. Palivizumab in congenital heart disease: should international guidelines be revised? Expert Opin Biol Ther. 2007;7(11):1615-1620 (Pubitemid 350161648)
46. Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Can J Cardiol. 2011;27(4):523.e11-523.e15
47. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev. 2009;10(3):148-153
48. Wilkesmann A, Ammann RA, Schildgen O, et al DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26(6):485-491 (Pubitemid 46847308)
49. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56(2):258-266
50. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872-1880
51. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195-1204
52. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics. 2008;121(2):235-243 (Pubitemid 351198444)
53. Asner S, Stephens D, Pedulla P, Richardson SE, Robinson J, Allen U. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J. 2013;32(10):1073-1076
54. Chemaly RF, Ghantoji SS, Shah DP, et al. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol. 2013; doi:10.1097/MPH.0000000000000086
55. Lo MS, Lee GM, Gunawardane N, Burchett SK, Lachenauer CS, Lehmann LE. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013;17(2):133-143
56. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220-1226
57. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19(4):589-596
58. Michaels MG, Fonseca-Aten M, Green M, et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009;13(4):451-456
59. Danziger-Isakov LA, Arslan D, Sweet S, Benden C, Goldfarb S, Wong J. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative. Pediatr Transplant. 2012;16(6):638-644
60. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics. 2007;120(4). Available at: www.pediatrics.org/ cgi/content/full/120/4/e1076
61. Zachariah P, Ruttenber M, Simões EA. Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr. 2012;160(5):827-831, e1
62. Giebels K, Marcotte JE, Podoba J, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43(2):169-174 (Pubitemid 351273044)
63. Winterstein AG, Eworuke E, Xu D, Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol. 2013;48(9):874-884
64. Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of palivizumab for prophylaxis of RSV disease in children with cystic fibrosis. [abstr] Proc Am Thorac Soc. 2005;2:A178
65. Kristensen K, Hjuler T, Ravn H, Simões EAF, Stensballe LG. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis. 2012;54(6):810-817
66. Elnazir B, Oni O, Hassan T, Greally P, Paes B. Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age? J Paediatr Child Health. 2012;48(11):1033-1038
67. Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol. 2009;44(1):96-98
68. Yamaguchi M, Sano Y, Dapat IC, et al. High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan. J Clin Microbiol. 2011;49(3):1034-1040
69. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917-1928 (Pubitemid 32553362)
70. Henderson FW, Collier AM, Clyde WA, Jr, Denny FW. Respiratory-syncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300(10):530-534 (Pubitemid 9167827)
71. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al Second Season Safety Study Group. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf. 2003;26(4):283-291 (Pubitemid 36363608)
72. Null D, Jr, Pollara B, Dennehy PH, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J. 2005;24(11):1021-1023 (Pubitemid 41689617)
73. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178(6):1555-1561 (Pubitemid 28558122)
74. Ramilo O, Sagos R, Saez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33(7):703-709
75. Berger A, Obwegeser E, Aberle SW, Langgartner M, Popow-Kraupp T. Nosocomial transmission of respiratory syncytial virus in neonatal intensive care and intermediate care units: a prospective epidemiologic study. Pediatr Infect Dis J. 2010;29(7):669-670
76. Katz BZ, Sullivan C. Respiratory syncytial virus prophylaxis in a tertiary care neonatal intensive care unit. Pediatr Infect Dis J. 2009;28(9):842-844
77. Ohler KH, Pham JT. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus. Am J Health Syst Pharm. 2013;70(15):1342-1346
78. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(suppl 5):S118-S126 (Pubitemid 37456909)
79. Meissner HC, Bocchini JA, Jr, Brady MT, Hall CB, Kimberlin DW, Pickering LK. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics. 2009;124(6):1676-1679
80. Belderbos ME, Houben ML, Wilbrink B, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics. 2011;127(6). Available at: www.pediatrics.org/cgi/content/full/127/ 6/e1513
81. Carbonell-Estrany X, Quero J, Bustos G, et al IRIS Study Group. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J. 2000;19(7):592-597 (Pubitemid 30469763)
82. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20(9):874-879 (Pubitemid 32880323)
83. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DSK, Todd JK, Simoes EAF. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics. 2006;117(2):349-356 (Pubitemid 46071597)
84. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815-820 (Pubitemid 40221022)
85. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806-814 (Pubitemid 40221021)
86. Meissner HC, Hall CB. Respiratory syncytial virus. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, eds. Feigin & Cherry's Textbook of Pediatric Infectious Diseases, 7th ed. Philadelphia, PA: Elsevier Saunders; 2013:2407-2434
87. Hervás D, Reina J, Hervás JA. Meteorologic conditions and respiratory syncytial virus activity. Pediatr Infect Dis J. 2012;31(10):e176- e181
88. Nielsen HE, Siersma V, Andersen S, et al. Respiratory syncytial virus infection - risk factors for hospital admission: a case-control study. Acta Paediatr. 2003;92(11):1314-1321 (Pubitemid 37465177)
89. Paynter S, Ware RS, Lucero MG, et al. Malnutrition: a risk factor for severe respiratory syncytial virus infection and hospitalization. Pediatr Infect Dis J. 2014;33(3):267-271
90. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011;15(5):iii-iv, 1-124
91. Wang EE, Law BJ, Robinson JL, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997;99 (3). Available at: www.pediatrics.org/cgi/content/full/99/3/e9 PubMed
92. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126(2):212-219
93. Zachariah P, Ruttenber M, Simões EA. Hospitalizations due to respiratory syncytial virus in children with congenital malformations. Pediatr Infect Dis J. 2011;30(5):442-445
94. Le Saux N, Gaboury I, MacDonald N. Maternal respiratory syncytial virus antibody titers: season and children matter. Pediatr Infect Dis J. 2003;22(6):563-564 (Pubitemid 36782199)
95. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J. 2007;26(suppl 11):S41-S45 (Pubitemid 350295029)
96. Banerji A, Bell A, Mills EL, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ. 2001;164(13):1847-1850 (Pubitemid 32702069)
97. Singleton RJ, Bulkow LR, Miernyk K, et al. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282-1290
98. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctôt KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ. 2009;12(4):361-370
99. Young M, Kandola K, Mitchell R, Leamon A. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and the Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health (Oxford). 2007;12(7):563-566 (Pubitemid 350075600)
100. Alaska State Virology Laboratory Weekly Report, April 12-19, 2004. Available at: http://dhss.alaska.gov/dph/labs/documents/pdfs/ASVL-WeeklyReport. pdf. Accessed April 24, 2014
101. Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics. 2002;110(2 pt 1). Available at: www.pediatrics.org/cgi/content/full/110/2/e20
102. Lowther SA, Shay DK, Holman RC, Clarke MJ, Kaufman SF, Anderson LJ. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J. 2000;19(1):11-17 (Pubitemid 30046610)
103. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(2):110-115 (Pubitemid 28096007)
104. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215-1224 (Pubitemid 27460986)
105. Iwane MK, Chaves SS, Szilagyi PG, et al. Disparities between black and white children in hospitalizations associated with acute respiratory illness and laboratory-confirmed influenza and respiratory syncytial virus in 3 US counties - 2002-2009. Am J Epidemiol. 2013;177(7):656-665
106. Welliver RC, Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010;26(9):2175-2181
107. US Food and Drug Administration. Memorandum. Background package for BLA 125283 motavizumab. 2010. Available at: www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ antiviraldrugsadvisorycommittee/ucm213825.pdf. Accessed April 24, 2014
108. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultrapotent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652-665 (Pubitemid 46527610)
109. Carbonell-Estrany X, Simões EA, Dagan R, et al; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a non-inferiority trial. Pediatrics. 2010;125(1). Available at: www.pediatrics.org/cgi/content/full/125/1/e35
110. Abarca K, Jung E, Fernández P, et al; Motavizumab Study Group. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J. 2009;28(4):267-272
111. Fernández P, Trenholme A, Abarca K, et al; Motavizumab Study Group. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10:38
112. Feltes TF, Sondheimer HM, Tulloh RM, et al Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):186-191
113. Bourgeois FT, Valim C, McAdam AJ, Mandl KD. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009;124(6). Available at: www.pediatrics.org/cgi/content/full/124/6/e1072
114. Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis. 2010;51 (2):185-188
115. Calõşkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med. 2013;368(15):1398-1407
116. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178(7):667-672
117. Poorisrisak P, Halkjaer LB, Thomsen SF, et al. Causal direction between respiratory syncytial virus bronchiolitis and asthma studied in monozygotic twins. Chest. 2010;138(2):338-344
118. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137-141 (Pubitemid 40105412)
119. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541-545 (Pubitemid 29381367)
120. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34-42, e1
121. Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA. 2012;307(17):1801-1802
122. ABIM Foundation. American Board of Internal Medicine; ACP-ASIM Foundation. American College of Physicians-American Society of Internal Medicine; European Federation of Internal Medicine. Medical professionalism in the new millennium: a physician charter. Ann Intern Med. 2002;136(3):243-246
123. Ubel PA, Jagsi R. Promoting population health through financial stewardship. N Engl J Med. 2014;370(14):1280-1281
124. Bentley A, Filipovic I, Gooch K, Buesch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK. Thorax. 2011;66(suppl 4):A136
125. Bentley A, Filipovic I, Gooch K, Büsch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev. 2013;3(1):18
126. Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr. 2009;35(1):4
127. Krilov LR, Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatrics. 2009;124(6):1682-1684
128. Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008;24(11):3223-3237
129. Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15(5):987-996
130. Neovius K, Buesch K, Sandström K, Neovius M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 2011;100(10):1306-1314
131. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics. 2007;25(1):55-71 (Pubitemid 46072368)
132. Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis. 2012;31(10):2703-2711
133. Smart KA, Lanctôt KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010;13(3):453-463
134. Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15(5):997-1018
135. Elhassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070-1076 (Pubitemid 44520638)
136. Embleton ND, Dharmaraj ST, Deshpande S. Cost-effectiveness of palivizumab in infancy. Expert Rev Pharmacoecon Outcomes Res. 2007;7(5):445-458 (Pubitemid 350120039)
137. Handforth J, Sharland M, Friedland JS. Prevention of respiratory syncytial virus infection in infants. BMJ. 2004;328(7447):1026-1027 (Pubitemid 38580821)
138. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3 pt 1):419-427 (Pubitemid 29424659)
139. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH; Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162(4):230-236 (Pubitemid 36437755)
140. Prescott WA, Jr, Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics. 2010;28(4):279-293
141. Prescott WA, Jr, Hutchinson DJ. Respiratory syncytial virus prophylaxis in special populations: Is it something worth considering in cystic fibrosis and immunosuppression? J Pediatr Pharmacol Ther. 2011;16(2):77-86
142. Rietveld E, Steyerberg EW, Polder JJ, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010;95(7):493-498
143. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114(6):1612-1619 (Pubitemid 41754927)
144. Owens DK, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154(3):174-180
145. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy. 2010;2(5):655-661
146. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147-6153
147. Schepens B, Ibañez LI, De Baets S, et al. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692-1701
148. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107(19):8800-8805
149. Empey KM, Peebles RS, Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 2010;50(9):1258-1267
150. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011;239(1):149-166
151. Haynes LM. Progress and challenges in RSV prophylaxis and vaccine development. J Infect Dis. 2013;208(suppl 3):S177-S183
152. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-1555
153. Régnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. Vaccine. 2013;31(40):4347-4354
154. Luongo C, Winter CC, Collins PL, Buchholz UJ. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol. 2013;87(4):1985-1996
155. Rigter A, Widjaja I, Versantvoort H, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS ONE. 2013;8(8):e71072
156. Magro M, Mas V, Chappell K, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA. 2012;109(8):3089-3094
157. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013;31(3):524-532
158. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592-598